Written Authority Required Drugs

Leukaemia - chronic lymphocytic leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with chronic lymphocytic leukaemia.

Patient eligibility

The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with chronic lymphocytic leukaemia.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib. 


Initial treatment

Apply for initial authority approval to prescribe PBS subsidised idelalisib to treat chronic lymphocytic leukaemia in writing and either:

All applications must include the completed:

Continuing treatment

To apply for continuing treatment with idelalisib for chronic lymphocytic leukaemia contact the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

This information was printed Sunday 26 May 2019 from https://www.humanservices.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/leukaemia-chronic-lymphocytic-leukaemia It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.humanservices.gov.au/individuals/site-notices when using this material.

Page last updated: 22 February 2019